•  
  •  
 

Abstract

Background: Treatment adherence in tuberculosis (TB) remains a major public health challenge in Indonesia. In West Kalimantan, high treatment interruption rates are driven by geographic, socioeconomic, and healthcare factors. This study identifies the risk factors linked to treatment interruption in the province.

Methods: A retrospective cohort study was using the System Information of Tuberculosis (SITB) database from 2019 to 2022 (n = 12,052). We used Kaplan-Meier analysis and Cox regression to identify treatment interruption risk factors, considering patient characteristics and geographic disparities.

Results: The overall treatment interruption rate was 6.62 % among new patients and 2.87 % among retreatment patients, with the highest risk occurring during the intensive treatment phase. Significant risk factors for treatment interruption included male sex (aHR = 1.18, 95 % CI: 1.01-1.39, p = 0.043), older age (>55 years, aHR = 15.2, 95 % CI: 6.29-36.9, p < 0.001), HIV positive status (aHR = 9.46, 95 % CI: 7.11-12.6, p < 0.001), and diabetes mellitus history (aHR = 1.51, 95 % CI: 1.21-1.89, p < 0.001). Rural districts showed higher treatment interruption rates due to limited healthcare access and cross-border mobility issues.

Conclusion: The study highlighted the urgent need for targeted interventions to reduce treatment interruption, particularly among older patients, males, and individuals with comorbidities. Strategies such as enhanced patient follow-up, mobile TB clinics, and integration of TB-HIV care are recommended. These findings provide critical insights for improving TB treatment programs in resource-limited settings.

Keywords: Tuberculosis, Treatment interruptions, Hazard ratio, Risk factors, Indonesia

References

[1] TBC Indonesia. Factsheet & country profile Indonesia. 2022 [cited 2023 Apr 22]. Available from: https://tbindonesia.or.id/pustaka_tbc/factsheet-country-profile-indonesia-2022/.

[2] Rauf A, Abu-Izneid T, Olatunde A, Ahmed Khalil A, Alhumaydhi FA, Tufail T, et al. COVID-19 pandemic: epidemiology, etiology, conventional and non-conventional therapies. Int J Environ Res Publ Health 2020;17(21). https://doi.org/10.3390/ijerph17218155.

[3] World Health Organization [WHO]. Global tuberculosis report 2021. Geneva: WHO; 2021 [cited 2022 Jul 13]. Available from: https://apps.who.int/iris/handle/10665/346387.

[4] Lolong DB, Aryastami NK, Kusrini I, Tobing KL, Tarigan I, Isfandari S, et al. Nonadherence to anti-tuberculosis treatment, reasons and associated factors among pulmonary tuberculosis patients in the communities in Indonesia. PLoS One 2023;18(8):e0287628. https://doi.org/10.1371/journal.pone.0287628.

[5] Lestari BW, Afifah N, McAllister S, Miranda AV, Herawati E, Hadisoemarto PF, et al. Determinants of adherence towards tuberculosis guidelines among Indonesian private practitioners: a qualitative study. BMJ Glob Health 2024;9(12). https://doi.org/10.1136/bmjgh-2024-015261.

[6] Lestari T, Fuady A, Yani FF, Putra I, Pradipta IS, Chaidir L, et al. The development of the national tuberculosis research priority in Indonesia: a comprehensive mixed-method approach. PLoS One 2023;18(2):e0281591. https://doi.org/10.1371/journal.pone.0281591.

[7] Surendra H, Elyazar IRF, Puspaningrum E, Darmawan D, Pakasi TT, Lukitosari E, et al. Impact of the COVID-19 pandemic on tuberculosis control in Indonesia: a nationwide longitudinal analysis of programme data. Lancet Global Health 2023;11(9):e1412-21. https://doi.org/10.1016/s2214-109x(23)00312-1.

[8] Kant S, Tyagi R. The impact of COVID-19 on tuberculosis: challenges and opportunities. Ther Adv Infect Dis 2021;8:20499361211016973. https://doi.org/10.1177/20499361211016973.

[9] The TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. Eur Respir J 2022;59(3):2102538. https://doi.org/10.1183/13993003.02538-2021.

[10] World Health Organization [WHO]. Definitions and reporting framework for tuberculosise2022 revision. Geneva: WHO; 2022 [updated 2022 Dec; cited 2023 Mar 18]. Available from: http://www.who.int/tb/publications/definitions/en/.

[11] Lee ET, Go OT. Survival analysis in public health research. Annu Rev Publ Health 1997;18:105-34. https://doi.org/10.1146/annurev.publhealth.18.1.105.

[12] R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2015 [cited 2016 Feb 29]. Available from: http://www.Rproject.org.

[13] Astutik E, Wahyuni CU, Manurung IFE, Ssekalembe G. Integrated model of a family approach and local support in tuberculosis case finding efforts in people with HIV/AIDS. Kesmas Natl Public Health J 2021;16(4):250-6. https://doi.org/10.21109/kesmas.v16i4.4955.

[14] Vijay S, Balasangameswara VH, Jagannatha PS, Saroja VN, Kumar P. Defaults among tuberculosis patients treated under DOTS in Bangalore City: a search for solution. Indian J Tubercul 2003;50(4):185-95.

[15] Maruza M, Albuquerque MF, Coimbra I, Moura LV, Montarroyos UR, Miranda Filho DB, et al. Risk factors for default from tuberculosis treatment in HIV-infected individuals in the state of Pernambuco, Brazil: a prospective cohort study. BMC Infect Dis 2011;11:351. https://doi.org/10.1186/1471-2334-11-351.

[16] Wang J, Fei Y, Shen H, Xu B. Gender difference in knowledge of tuberculosis and associated health-care seeking behaviors: a cross-sectional study in a rural area of China. BMC Public Health 2008;8:354. https://doi.org/10.1186/1471-2458-8-354.

[17] Gayline V, Anthony W, Eliud M. Unemployment and underemployment in Kenya: a gender gap analysis. Economics 2013;2(2):7-16. https://doi.org/10.11648/j.eco.20130202.11.

[18] Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007;4(7):e238. https://doi.org/10.1371/journal.pmed.0040238.

[19] Atkins S, Lewin S, Ringsberg KC, Thorson A. Provider experiences of the implementation of a new tuberculosis treatment programme: a qualitative study using the normalization process model. BMC Health Serv Res 2011;11:275. https://doi.org/10.1186/1472-6963-11-275.

[20] Zafar Ullah AN, Huque R, Husain A, Akter S, Akter H, Newell JN. Tuberculosis in the workplace: developing partnerships with the garment industries in Bangladesh. Int J Tubercul Lung Dis 2012;16(12):1637-42. https://doi.org/10.5588/ijtld.12.0378.

[21] Ministry of Health, Division of Leprosy, Tuberculosis and Lung Disease. Guidelines for management of tuberculosis and leprosy in Indonesia. Jakarta: NTLD; 2023 [cited 2023 Mar 15]. Available from: http://www.kemenkes.co.id.

[22] Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tubercul Lung Dis 2013;17(3):299-307. https://doi.org/10.5588/ijtld.12.0537.

[23] Beith A, Eichler R, Weil D. Performance-based incentives for health: a way to improve tuberculosis detection and treatment completion? CGD Working Paper no. 122. [updated 2007 Apr 23; cited 2023 Mar 15]. Available from: https://www.cgdev.org/sites/default/files/13544_file_TB_final.pdf.

[24] Masini EO, Mansour O, Speer CE, Addona V, Hanson CL, Sitienei JK, et al. Using survival analysis to identify risk factors for treatment interruption among new and retreatment tuberculosis patients in Kenya. PLoS One 2016;11(10):e0164172. https://doi.org/10.1371/journal.pone.0164172.

Download

Share

COinS